Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
暂无分享,去创建一个
A. Duggal | Xiaofeng Wang | V. Vachharajani | Gretchen L. Sacha | Omar Mehkri | Xiaozhen Han | Prabalini Rajendram | Vidula Vachharajani
[1] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.
[2] Samantha K. Brenner,et al. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. , 2020, JAMA internal medicine.
[3] M. Massari,et al. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[4] R. Porcher,et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.
[5] Bao-Ping Tian,et al. Efficacy of tocilizumab treatment in severely ill COVID-19 patients , 2020, Critical Care.
[6] A. Sönnerborg,et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID‐19: a retrospective cohort study , 2020, medRxiv.
[7] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[8] M. Al-Jaghbeer,et al. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study , 2020, EClinicalMedicine.
[9] C. D. Dela Cruz,et al. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 , 2020, Chest.
[10] D. Hanauer,et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19 , 2020, medRxiv.
[11] A. Zangrillo,et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study , 2020, European Journal of Internal Medicine.
[12] M. Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[13] J. Badie,et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients , 2020, Médecine et Maladies Infectieuses.
[14] A. Omrani,et al. Tocilizumab for the treatment of severe coronavirus disease 2019 , 2020, Journal of medical virology.
[15] M. Metra,et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy , 2020, Autoimmunity Reviews.
[16] Xiaohu Zheng,et al. Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.
[17] Jared Radbel,et al. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome , 2020, Chest.
[18] Eun Ji Kim,et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.
[19] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[20] Dong Liu,et al. Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.
[21] D. McGonagle,et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.
[22] F. Marincola,et al. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 , 2020, Journal for ImmunoTherapy of Cancer.
[23] S. Antinori,et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.
[24] D. Wang,et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.
[25] Giacomo Grasselli,et al. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. , 2020, JAMA.
[26] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[27] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[28] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[29] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[30] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[31] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[32] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[33] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[34] F. Anjum,et al. Tocilizumab , 2019, Reactions Weekly.
[35] J. Singer,et al. Days alive and free as an alternative to a mortality outcome in pivotal vasopressor and septic shock trials☆,☆☆,★ , 2018, Journal of critical care.
[36] S. Perlman,et al. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.
[37] Kwok-Hung Chan,et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. , 2013, The Journal of general virology.
[38] 橋本 卓也. 留学体験記 (Imperial College London) , 2012 .
[39] Svetlana K. Eden,et al. Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies* , 2009, Critical care medicine.
[40] P. Austin. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.
[41] N. Nishimoto,et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. , 2008, Blood.
[42] Peter C Austin,et al. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study , 2007, Statistics in medicine.
[43] Z. Li,et al. Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS† , 2006, The Journal of pathology.
[44] H. Tsutsumi,et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections† , 2006, Journal of medical virology.
[45] Y. Lau,et al. Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells , 2005, Blood.
[46] Jing Li,et al. Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome , 2004, Infection and Immunity.
[47] Yi Guan,et al. Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.
[48] E. Ross,et al. Philosophy of Science Association , 2022 .